GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Genomma Lab Internacional SAB de CV (MEX:LABB) » Definitions » Beneish M-Score

Genomma Lab InternacionalB de CV (MEX:LABB) Beneish M-Score : -2.35 (As of Mar. 27, 2025)


View and export this data going back to 2008. Start your Free Trial

What is Genomma Lab InternacionalB de CV Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.35 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Genomma Lab InternacionalB de CV's Beneish M-Score or its related term are showing as below:

MEX:LABB' s Beneish M-Score Range Over the Past 10 Years
Min: -3.61   Med: -2.54   Max: -1.81
Current: -2.35

During the past 13 years, the highest Beneish M-Score of Genomma Lab InternacionalB de CV was -1.81. The lowest was -3.61. And the median was -2.54.


Genomma Lab InternacionalB de CV Beneish M-Score Historical Data

The historical data trend for Genomma Lab InternacionalB de CV's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomma Lab InternacionalB de CV Beneish M-Score Chart

Genomma Lab InternacionalB de CV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.45 -2.42 -2.63 -2.92 -2.35

Genomma Lab InternacionalB de CV Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.92 -2.69 -2.60 -2.67 -2.35

Competitive Comparison of Genomma Lab InternacionalB de CV's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomma Lab InternacionalB de CV's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Genomma Lab InternacionalB de CV's Beneish M-Score falls into.


';

Genomma Lab InternacionalB de CV Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Genomma Lab InternacionalB de CV for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.2135+0.528 * 0.9549+0.404 * 1.0517+0.892 * 1.1299+0.115 * 0.8024
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0173+4.679 * -0.036694-0.327 * 0.9374
=-2.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Total Receivables was MXN5,407 Mil.
Revenue was 4665.574 + 5092.514 + 4651.495 + 4197.32 = MXN18,607 Mil.
Gross Profit was 2941.672 + 3272.001 + 2977.7 + 2739.671 = MXN11,931 Mil.
Total Current Assets was MXN12,398 Mil.
Total Assets was MXN24,083 Mil.
Property, Plant and Equipment(Net PPE) was MXN3,559 Mil.
Depreciation, Depletion and Amortization(DDA) was MXN360 Mil.
Selling, General, & Admin. Expense(SGA) was MXN7,647 Mil.
Total Current Liabilities was MXN6,753 Mil.
Long-Term Debt & Capital Lease Obligation was MXN5,065 Mil.
Net Income was 473.493 + 660.06 + 631.645 + 372.106 = MXN2,137 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = MXN0 Mil.
Cash Flow from Operations was 1271.952 + 1463.415 + 412.078 + -126.455 = MXN3,021 Mil.
Total Receivables was MXN3,943 Mil.
Revenue was 3525.153 + 4393.239 + 4370.506 + 4178.228 = MXN16,467 Mil.
Gross Profit was 2112.747 + 2741.947 + 2664.8 + 2563.732 = MXN10,083 Mil.
Total Current Assets was MXN10,670 Mil.
Total Assets was MXN20,738 Mil.
Property, Plant and Equipment(Net PPE) was MXN3,415 Mil.
Depreciation, Depletion and Amortization(DDA) was MXN271 Mil.
Selling, General, & Admin. Expense(SGA) was MXN6,653 Mil.
Total Current Liabilities was MXN6,622 Mil.
Long-Term Debt & Capital Lease Obligation was MXN4,234 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(5407.178 / 18606.903) / (3943.316 / 16467.126)
=0.290601 / 0.239466
=1.2135

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(10083.226 / 16467.126) / (11931.044 / 18606.903)
=0.612325 / 0.641216
=0.9549

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (12398.397 + 3558.571) / 24082.515) / (1 - (10670.395 + 3414.811) / 20738.487)
=0.337404 / 0.320818
=1.0517

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=18606.903 / 16467.126
=1.1299

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(271.441 / (271.441 + 3414.811)) / (359.586 / (359.586 + 3558.571))
=0.073636 / 0.091774
=0.8024

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(7647.249 / 18606.903) / (6652.953 / 16467.126)
=0.41099 / 0.404014
=1.0173

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((5064.81 + 6753.067) / 24082.515) / ((4233.93 + 6622.353) / 20738.487)
=0.490724 / 0.523485
=0.9374

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(2137.304 - 0 - 3020.99) / 24082.515
=-0.036694

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Genomma Lab InternacionalB de CV has a M-score of -2.35 suggests that the company is unlikely to be a manipulator.


Genomma Lab InternacionalB de CV Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Genomma Lab InternacionalB de CV's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Genomma Lab InternacionalB de CV Business Description

Traded in Other Exchanges
Address
Avenida Antonio Dovali Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Genomma Lab InternacionalB de CV Headlines

No Headlines